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BACKGROUND: Data continue to emerge on the relative merits of different treatment modalities for prostate cancer. The objective of
this study was to compare patient-reported quality-of-life (QOL) outcomes after proton therapy (PT) and intensity-modulated radia-
tion therapy (IMRT) for prostate cancer. METHODS: A comparison was performed of prospectively collected QOL data using the
Expanded Prostate Cancer Index Composite (EPIC) questionnaire. QOL data were collected during the first 2 years after treatment
for men who received PT and IMRT. PT was delivered to 1243 men at a single center at doses from 76 grays (Gy) to 82 Gy. IMRT was
delivered to 204 men who were included in the Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment
(PROSTQA) study in doses from 75.6 Gy to 79.4 Gy. The Wilcoxon rank-sum test was used to compare EPIC outcomes by modality
using baseline-adjusted scores at different time points. Individual questions were assessed by converting to binary outcomes and
testing with generalized estimating equations. RESULTS: No differences were observed in summary score changes for bowel, urinary
incontinence, urinary irritative=obstructive, and sexual domains between the 2 cohorts. However, more men who received IMRT
reported moderate=big problems with rectal urgency (P50.02) and frequent bowel movements (P50.05) than men who received
PT. CONCLUSIONS: There were no differences in QOL summary scores between the IMRT and PT cohorts during early follow-up (up
to 2-years). Response to individual questions suggests possible differences in specific bowel symptoms between the 2 cohorts. These
outcomes highlight the need for further comparative studies of PT and IMRT. Cancer 2014;120:1076–82. VC 2013 The Authors. Cancer
published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Crea-
tive Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original
work is properly cited, the use is non- commercial and no modifications or adaptations are made.
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INTRODUCTION
Conformal radiotherapy (RT) techniques for prostate cancer are expected to reduce urinary and rectal toxicity1 and
improve disease control through facilitation of dose escalation.2 The increased costs associated with these techniques3 have
led payors and insurers to demand clinical data demonstrating improved disease control and=or less toxicity.
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Several comparative-effectiveness studies of conven-
tional radiation therapy, 3-dimensional conformal
radiation therapy (3DCRT), intensity-modulated RT
(IMRT), and proton therapy (PT) have been reported.
Those studies have in common a reliance on Medicare
claims as surrogates for actual clinical outcomes, but
they differ somewhat in their findings.4-7 The use of
Medicare claims rather than medical records may be a
weakness, because medical claims codes identify inter-
ventions that may not reflect the relevant endpoints of
disease control, specific treatment-related toxicity, or
patient-reported quality of life (QOL). Some of the
reports have attracted considerable criticism,8,9 and the
authors of 1 study acknowledge the limitations of the
Medicare database and the need for patient-reported
QOL outcomes.7 A randomized trial comparing PT and
IMRT has been opened, but the comparative impact on
late effects will not be known for some years (registered
as National Clinical Trial NCT01617161). We com-
pared prospectively collected QOL outcomes of >1400
men from 2 databases who received treatment with PT
or IMRT.
MATERIALS AND METHODS
Materials and Patients
The Expanded Prostate Cancer Index Composite (EPIC)-
26 questionnaire is a validated instrument that has 5
domains, including urinary incontinence (UI) (4 ques-
tions), urinary irritative=obstructive (UO) (4 questions),
bowel function (BS) (6 questions), sexual function (SS) (6
questions), and hormonal function (HF) (5 questions);
each subscale is scored from 0 to 100, in which 100 repre-
sents no problems and 0 represents substantial and signifi-
cant problems with the specific subscale.10 Prospectively
collected data from EPIC questionnaires from 2 patient
cohorts that received PT and IMRT, respectively, were
compared.
The University of Florida Institutional Review
Board approved the study, which included 1482 men
with localized prostate cancer who were treated at the
University of Florida with passively scattered PT between
2006 and 2010. Patients were excluded if they failed to
complete treatment (n5 6), did not consent to study
inclusion (n5 19), or received hypofractionated PT at
2.5 cobalt gray equivalent per fraction or weekly docetaxel
on treatment protocols (n5 71), or pelvic lymph node
irradiation (n5 45), leaving a total of 1243 men in the
PT cohort. The EPIC questionnaires were collected on
paper forms (before March 2009) or by a secure online
medical records portal accessed over the Internet (after
March 2009) at 6 months, 1 year, then annually.
Specific details of the PT simulation and treatment
have been previously reported.11 Patients received 1.8 to 2
grays (Gy) per fraction, and the majority (99%;
n5 1226) received between 78 Gy and 82 Gy (relative
biologic effectiveness) at 2 Gy (relative biologic effective-
ness) per fraction.
The second cohort included 204 men from the pre-
viously reported Prostate Cancer Outcomes and Satisfac-
tion with Treatment Quality Assessment (PROSTQA)
study who were treated at 9 university-affiliated hospitals
with IMRT and who had completed EPIC-26 question-
naires before treatment and then at 2 months, 6 months,
12 months, and 24 months after treatment. These
patients received treatment between March 2003 and
March 2006, according to individual institutional poli-
cies, which consisted of IMRT to the prostate, with or
without seminal vesicles, without pelvic RT, at doses
from 75.6 to 79.2Gy at 1.8 to 2.0 Gy per fraction.12
Data on actual doses delivered to the IMRT patients
were not available, but minimum and maximum doses
to the planning target volume (PTV) were available for
comparison with the same dose parameters in the PT
cohort. Because of variability in hormone use between
the cohorts, differences in hormonal function or hormo-
nal questions were not investigated.
Statistics
SAS and JMP software were used for all statistical analyses
(SAS Institute, Cary, NC). Differences between the 2
cohorts of patients in pretreatment patient-specific, dis-
ease-specific, and treatment-specific characteristics were
assessed using the Fisher exact test for categorical variables
and the Wilcoxon rank-sum test for continuous variables
(Table 1). Scores for the EPIC were calculated as previ-
ously described.13,14 The 6-month, 1-year, and 2-year
post-treatment scores for each modality were compared
with the baseline data for that modality using the Wil-
coxon signed-rank sum test, which is a nonparametric
analog to a t test for paired data. Differences from pre-
treatment values>50% of the standard deviation15 at any
point in time were considered to represent the minimally
detectable difference. Differences in pretreatment scores
for the various subscales between the 2 cohorts were
assessed with the Wilcoxon rank-sum test. The same
method was used to compare baseline-adjusted outcomes
between the 2 modalities at 6 months, 1 year, and 2 years
after treatment; baseline adjustment for each patient and
each domain was accomplished by subtracting the
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baseline score from the 6-month, 1-year, and 2-year
scores. Patients without a baseline score were excluded
from the analysis. Because multiple domains were assessed
for each patient, a post hoc Bonferroni adjustment was
applied to the resulting P values (Tables 2 and 3). An
adjusted P value < .05 was considered statistically
significant.
Two approaches were used to analyze dichotomized
responses to each question covering urinary, bowel, and
sexual function, as previously reported.16 Baseline differ-
ences in individual question responses between the 2
modalities were assessed with the Fisher exact test. Six-
month, 1-year, and 2-year responses were assessed simul-
taneously using repeated-measures generalized estimating
equations with unstructured correlation through PROC
GENMOD in SAS (Table 4). The primary prognostic
factor in each model was treatment modality, but baseline
response, use of androgen-deprivation therapy (ADT),
age (<65 years vs 65 years), and prostate size were
entered into the models as covariates to control. A post
TABLE 1. Patient-Specific, Cancer-Specific, and
Treatment-Specific Characteristics
No. of Patients (%)
Characteristic
IMRT
(n 5 204)
PT
(n 5 1243) P
Age: Mean [range], y 69 [46–84] 66 [40 to >89] < .001
Body mass index:
Mean 6 SD, kg/m2
28.6 6 5.5 28.2 6 4.3 .64
Prostate size:
Mean 6 SD, mL
49.5 6 27.2 41.5 6 20.7 .001
Race < .001
White 166 (81) 1132 (91)
Black 34 (17) 77 (6)
Other 4 (2) 34 (3)
PSA, ng/mL .12
<4 37 (17) 205 (17)
4-10 128 (63) 862 (69)
>10 39 (19) 176 (14)
Gleason score .28
<7 104 (51) 659 (53)
7 86 (42) 466 (37)
>7 14 (7) 118 (10)
Clinical tumor classificationa .61
T1 148 (73) 922 (74)
T2 56 (27) 317 (26)
T3 0 (0) 3 (<1)
Overall risk level .41
Low 83 (41) 567 (46)
Intermediate 94 (46) 532 (43)
High 27 (13) 143 (11)
ADT 49 (24) 181 (15) .001
PTVmin: Median
[range], Gy
70.9 [40.7-90.2] 74.1 [40.0-80.7] < .001
PTVmax: Median
[range], Gy
81.5 [45.0-107.0] 83.2 [60.5-93.3] < .001
Abbreviations: ADT, androgen-deprivation therapy; Gy, grays; IMRT,
intensity-modulated radiotherapy; PSA, prostate-specific antigen; PT, pro-
ton therapy; PTVmin, minimum dose to the planned target volume;
PTVmax, maximum dose to the planned target volume; SD, standard
deviation.
a One patient who received proton therapy had no tumor classification infor-
mation available.
TABLE 2. Raw Expanded Prostate Cancer Index
Composite (EPIC) Scores With Adjusted P Values
(Absolute Shift Compared With Baseline)
EPIC Score
Proton Therapy IMRT
EPIC Domain at
Follow-Up Median Min Max Median Min Max Pa
Bowel summary
6 mo 0 283 46 0 263 58 .17
1 y 24 283 46 0 271 58 .92
2 y 24 271 29 0 279 67 .99
Urinary incontinence
6 mo 0 267 60 0 271 46 .31
1 y 0 2100 52 0 271 34 .99
2 y 0 2100 56 0 256 44 .99
Urinary irritative/obstructive
6 mo 0 288 56 0 294 38 .99
1 y 0 275 50 0 263 50 .27
2 y 0 275 50 0 250 38 .99
Sexual summaryb
6 mo 0 2100 100 0 294 58 .99
1 y 0 2100 92 0 296 58 .99
2 y 0 2100 100 0 283 71 .99
Abbreviations: EPIC, Expanded Prostate Cancer Index Composite; IMRT,
intensity-modulated radiotherapy; Max, maximum; Min, minimum.
aP values were determined using the Wilcoxon rank-sum test with Bonfer-
roni adjustment.
b Sexual summary scores were calculated for men who did not receive
androgen-deprivation therapy.
TABLE 3. Percentage of Men With Minimally De-
tectable Differences From Their Baseline Expanded
Prostate Cancer Index Composite Scoresa
EPIC Domain at Follow-Up Periods PT, % IMRT, % Pb
Bowel summary
6 mo 25 39 .002
1 y 41 37 .99
2 y 37 38 .99
Urinary incontinence
6 mo 22 28 .36
1 y 31 29 .99
2 y 32 34 .99
Urinary irritative/obstructive
6 mo 18 25 .99
1 y 23 20 .99
2 y 17 18 .99
Sexual summary
6 mo 27 31 .99
1 y 36 36 .99
2 y 40 41 .99
Abbreviations: EPIC, Expanded Prostate Cancer Index Composite; IMRT,
intensity-modulated radiotherapy; PT, Proton Therapy.
a These represent declines in scores >50% from baseline.
bP values were determined using the Wilcoxon rank-sum test with Bonfer-
onni adjustment.
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hoc Bonferroni adjustment also was included to adjust for
the 21 questions evaluated (excluding the hormone func-
tion questions, which were not used).
RESULTS
Patient-specific and treatment-specific characteristics are
illustrated in Table 1. IMRT patients treated were older
(median age, 69 vs 66 years; P< .001), had larger prostate
volumes (mean, 49.5 vs 41.5 g; P5 .0014), were less
likely to be white (81% vs 91% white; P< .001), were
more likely to receive ADT (24% vs 15%; P5 .00013),
and received both a lower minimum dose to the PTV
(median, 70.9 vs 74.1 Gy; P< .001) and a lower maxi-
mum PTV dose (median, 81.5 vs 83.2Gy; P< .001).
EPIC summary scores at baseline, 6 months, 1 year,
and 2 years after treatment are depicted in Figure 1A-D
for the PT and IMRT cohorts. After treatment, the only
changes in summary scores from baseline that met the
minimally detectable difference were observed for bowel
summary at 6 months, 1 year, and 2 years for IMRT and
for bowel summary at 1 year and 2 years for PT (Fig. 1A-
D). Both groups had declines in bowel summary scores,
but there were no statistically significant differences in
QOL changes between groups for BS, UI, UO, or SS (SS
was analyzed only among men who did not receive ADT)
at any time (Table 2). When examining the percentage of
men who had a minimally detectable difference at the var-
ious time points for the different summary scores, the
only remarkable difference between the IMRT and PT
cohorts was for the bowel summary component at the 6-
month follow-up (Table 3).
An analysis of individual items comprising each do-
main also was planned and performed. At baseline, the
only differences between the 2 cohorts were that men in
the IMRT cohort were more likely to report baseline
moderate=big problems with hematuria (P5 0.04), daily
urinary leakage (P5 .02), bloody stools (P5 .02), and
rectal pain (P5 .04). Men in the IMRT cohort also
reported more moderate=big problems within the sexual
domain, including poor erections, difficulty with
TABLE 4. Outcomes by Specific Expanded Prostate Cancer Index Composite Question
Baseline 6 Months 1 Year 2 Years
Question IMRT, % PT, % Pa IMRT, % PT, % IMRT, % PT, % IMRT, % PT, % Pb Pc
No. of patients answering EPICd 204 1212 192 1115 191 1093 177 963
Urinary irritation/obstruction
Dysuria 1 0 .35 6 3 2 5 1 2 .50 .99
Hematuria 1 0 .04 2 1 1 1 2 1 .33 .99
Weak stream 15 9 .03 12 7 15 11 11 8 .07 .99
Frequency 15 13 .38 17 12 15 14 13 11 .48 .99
Urinary incontinence
Leaking > daily 6 3 .02 10 3 9 5 7 5 .008 .16
Frequent dribbling 2 2 .72 2 3 4 4 3 4 .25 .99
Any pad use 1 2 .5 4 3 3 4 5 4 .58 .99
Leaking problem 2 1 .33 5 2 5 3 5 4 .06 .99
Overall urinary problem 10 8 .32 11 8 13 11 11 10 .68 .99
Bowel function
Urgency 3 2 .45 9 5 13 8 15 7 .001 .02
Frequency 2 1 .39 8 3 8 6 10 4 .003 .05
Fecal incontinence 1 1 .98 4 2 3 3 3 3 .28 .99
Bloody stools 2 0 .04 2 2 6 8 7 8 .06 .99
Rectal pain 3 1 .02 5 2 3 3 6 2 .19 .99
Overall bowel problem 3 2 .09 8 4 10 9 11 7 .21 .99
Sexual functione
Poor erections 36 25 .003 46 33 49 41 53 42 .24 .99
Difficulty with orgasm 31 21 .003 40 27 45 32 42 32 .06 .99
Erection not firm 47 33 < .001 56 39 59 47 59 49 .21 .99
Erections not reliable 45 34 .01 51 41 58 47 60 48 .19 .99
Poor sexual function 34 29 .18 43 35 46 41 47 44 .71 .99
Overall sexuality problem 17 21 .29 29 29 30 36 33 35 .36 .99
Abbreviations: EPIC, Expanded Prostate Cancer Index Composite; IMRT, intensity-modulated radiotherapy; PT, proton therapy.
a These P values were determined using the Fisher exact test.
b These P values were determined using a generalized estimating equation with the values adjusted for baseline difference, androgen-deprivation therapy, age,
and prostate size.
c These P values also were determined using a generalized estimating equation with the values adjusted for baseline difference, androgen-deprivation therapy,
age, and prostate size but included the addition of a Bonferroni adjustment for 21 questions.
d These were recorded in absolute numbers.
e Sexual function was reported for patients who did not receive androgen-deprivation therapy.
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orgasms, erections not sufficient for intercourse, and
unreliable erections (all P< .01) (Table 4). When com-
parisons over time were controlled for differences between
groups in age, prostate size, and ADT use as well as base-
line QOL, there were no significant differences between
the cohorts except for more frequent reports in the IMRT
cohort of “moderate” or “big problems” with rectal ur-
gency (P5 .02) and bowel frequency (P5 .05).
DISCUSSION
The study reported herein compares patient-reported
QOL outcomes in PT and IMRT cohorts using the
EPIC questionnaire. No significant differences were
observed in QOL EPIC summary scores for bowel, uri-
nary, or sexual function between the IMRT and PT
cohorts, despite higher minimum and maximum PTV
doses in the PT cohort, a factor that is expected to be
associated with higher toxicity.
EPIC urinary summary scores were similar between
the IMRT and PT cohorts in this study, concurring with
similar urinary toxicity rates between IMRT and PT sug-
gested by surrogate data reported in the Medicare stud-
ies.5,6,17 However, the EPIC bowel outcomes in this study
did not correlate with findings in 2 of the Medicare stud-
ies,5,6 which suggested worse bowel toxicity with PT than
with IMRT. TheMedicare studies have been criticized for
their reliance on surrogate data rather than actual clinical
data, such as using colonoscopy claims to conclude rectal
toxicity. Furthermore, absence of any clinical and treat-
ment details in the Medicare studies also may have con-
founded conclusions, because radiation dose, dose
fractionation, and dose distribution, the most important
predictive factors for gastrointestinal toxicity, were not
available and could have been significantly impacted by
the dose-escalation studies being performed during the
study period at the 2 proton centers.12,18 In contrast to
the Medicare studies, the current study is based on pro-
spectively collected, actual patient-reported clinical out-
comes using the same QOL instrument and acquisition
times between the PT and IMRT cohorts, and, as such,
Figure 1. Expanded Prostate Cancer Index Composite (EPIC) summary scores are illustrated over time for men who received
intensity-modulated radiotherapy (IMRT) or proton therapy (PT) for prostate cancer. Bar-and-whisker graphs at baseline and at 6
months (6M), 1 year (1Y), and 2 years (2Y) after proton therapy or intensity-modulated radiotherapy illustrate (A) bowel summary
scores, (B) urinary incontinence scores, (C) urinary irritative=obstructive scores, and (D) sexual summary scores (no androgen-
deprivation therapy). The bottom whisker represents the cutoff score for the lowest 5%, the bottom bar represents the cutoff
score for the lowest quartile, the blue line represents the median score, the top of the bar represents the cutoff score for the top
quartile, and the top of the whisker represents the cutoff score for the top 5%. At the bottom of the graph, an asterisk indicates
a statistically significant change from baseline score for each treatment modality and time point, and a pound sign indicates a
statistically significant and minimally detectable change (>50% of the baseline standard deviation) from the baseline score.
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should provide a more reliable comparison of functional
outcomes.
In this study, bowel summary scores were similar
between the groups, correlating with the findings by Yu
et al,7 who reported on a more recent Medicare patient
population that included patients who received treatment
at different proton centers. The results also are similar to
those recently reported by Gray et al,19 who compared
QOL outcomes of 95 men who received PT at Massachu-
setts General Hospital using the Talcott Prostate Symp-
tom Index20 with men who received IMRT from the
PROSTQA database using the EPIC questionnaire; those
authors reported that little difference was demonstrated in
bowel problems>6 months after treatment.
IMRT and PT both produce “high radiation dose”
volumes that conform to the target; IMRT does so at the
expense of exposing a larger volume of nontargeted tissue
to “low and moderate radiation doses.”21,22 Thus, toxic-
ities and functional outcomes related to high radiation
dose exposure, such as rectal bleeding, are expected to be
similar between IMRT and PT if target doses and daily
doses are similar.22,23 Conversely, the rate of toxicities
related to larger volumes of nontargeted tissue receiving
low-dose and moderate-dose radiation exposure might be
expected to be higher with IMRT than with PT. In the
current study, the rate of rectal bleeding tended to being
worse in the PT cohort, which may be explained by the
higher prescription doses received in the PT cohort. Stud-
ies investigating rectal toxicities other than bleeding—
such as rectal syndrome (which includes rectal urgency),
frequency, and incontinence—have demonstrated corre-
lations with the volumes of the rectum receiving both
high and low to moderate doses.18,24,25 Those studies
focused on patients who received 3DCRT rather than
IMRT, but the dose-volume relations serve to demon-
strate the type of toxicity improvements that might be
expected with reductions in the volume of rectum exposed
to low to moderate radiation doses using PT compared
with IMRT. Therefore, a potentially important finding of
the current study is the analysis that identified signifi-
cantly worse bowel urgency and bowel frequency in the
IMRT group, a problem that affects QOL and can persist
more than 10 years after radiation.26 Nevertheless, alter-
nate explanations, such as differing use of image-guided
therapy, differing use of aspirin or other anticoagulants,
target margins, interobserver variability, older age, or
larger prostate volumes in the IMRT cohort, also could
influence these results.27
Recent research has investigated the impact of differ-
ent rectal complications on global QOL after radiation
therapy for prostate cancer. Krol et al28 evaluated anorec-
tal function in 85 men at least 1 year after conventional-
dose prostate RT using the EPIC questionnaire, the Fecal
Incontinence QOL scale, and anal manometry. Those
authors observed that fecal incontinence and rectal ur-
gency most greatly influenced overall QOL along with
impaired anal resting pressure. It was also demonstrated
that urgency of defecation has a more severe impact on
patient-reported QOL than rectal bleeding, despite clini-
cians’ greater concern with rectal bleeding, which can be
treated and resolved, compared with urgency, which can
worsen over time and for which there is little treatment
for its symptomology.29 Therefore, these differences in
discreet rectal symptoms between PT and IMRT treat-
ments, as assessed from patient-reported outcomes, are in-
triguing and warrant further evaluation.
The strengths of the current study are the prospec-
tive design for data collection, the use of patient-reported
outcomes (PRO) from contemporary IMRT and PT se-
ries, the use of a common QOL instrument, and the col-
laborative effort between institutions that use IMRT and
those that use PT. Although patients were not randomized
to RT modalities, baseline information on clinical factors,
QOL, and RT details permitted some adjustments for dif-
ferences between the cohorts. Nevertheless, no level of sta-
tistical manipulation can account for how PT patients
may have sought out (and traveled) to receive treatment in
expectation of fewer side effects and better QOL. This
exact criticism, however, can be made for the Medicare
studies, which also were unable to statistically account for
these differences. Another potential weakness is that the
patients receiving PT were treated consistently at a single
academic center, whereas the patients receiving IMRT
were treated at 9 different academic centers; however, the
same could be said for the Medicare studies, in which the
vast majority of patients who were treated before 2008
would have been treated at 1 institution.18 Additional
weaknesses include that our comparative analysis plan was
post hoc, although the QOL data were collected prospec-
tively, and the difference in EPIC data collection between
the cohorts—with patients who received IMRT under-
going a telephone-assisted interview whereas those who
received PT read and completed their questionnaires
without assistance—potentially could lead to bias in ei-
ther direction.
The findings from this study provide evidence of
excellent and comparable QOL outcomes for patients
with prostate cancer who receive either contemporary
IMRT or PT. Although similar bowel, urinary, and sexual
scores were observed with IMRT and PT, potential
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differences in specific functional outcomes, such as bleed-
ing, rectal urgency, and bowel frequency, also were
observed and may reflect differences in radiation dose dis-
tributions between IMRT and PT, differences in patient
characteristics, or both. Further investigation will be nec-
essary to validate these findings and to identify the under-
lying mechanisms that account for them.
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